Groupama Asset Management’s ResMed RMD Stock Holding History

Groupama Asset Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$211K	Sell	941 -1,537	-62%	-$383K	﹤0.01%	382
2025 Q4	$597K	Sell	2,478 -180	-7%	-$46K	0.01%	316
2025 Q3	$728K	Sell	2,658 -2,834	-52%	-$774K	0.01%	305
2025 Q2	$1.4M	Buy	5,492 +4,368	+389%	+$1.04M	0.02%	235
2025 Q1	$247K	Buy	+1,124	New	+$262K	﹤0.01%	380
2024 Q4	–	Sell	-3,514	Closed	-$689K	–	484
2024 Q3	$689K	Buy	3,514 +17	+0.5%	+$3.8K	0.02%	305
2024 Q2	$669K	Sell	3,497 -1,748	-33%	-$355K	0.01%	342
2024 Q1	$2.16M	Sell	5,245 -7,374	-58%	-$1.35M	0.04%	221
2023 Q4	$2.17M	Buy	+12,619	New	+$1.94M	0.06%	195

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Groupama Asset Management's RMD Position: Q1 2026 in Review

Groupama Asset Management reduced its ResMed (RMD) stake by 62% in Q1 2026, selling an estimated $383K and leaving 941 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #382.

Groupama Asset Management first reported a position in RMD in Q4 2023 and has held it in 9 quarters since. The position peaked at $2.17M in Q4 2023. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Groupama Asset Management held 941 shares of ResMed worth $211K as of Q1 2026.
Groupama Asset Management sold 1,537 ResMed shares in Q1 2026, an estimated $383K.
ResMed made up ﹤0.01% of Groupama Asset Management's portfolio in Q1 2026, its #382 holding.
Groupama Asset Management first reported a position in ResMed in Q4 2023 and has held it in 9 quarters since.
Groupama Asset Management's ResMed position peaked at $2.17M in Q4 2023.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Groupama Asset Management's 13F filing for Q1 2026, filed 22 May 2026.